<DOC>
	<DOCNO>NCT00551954</DOCNO>
	<brief_summary>Endothelial dysfunction ( ED ) suggest possible causal link postprandial hyperglycemia cardiovascular event patient type 2 diabetes . Recent trial demonstrate reduction cardiovascular event treatment alpha glucosidase inhibitor acarbose - drug mainly reduce postprandial glucose excursion . We interest whether patient newly diagnose type 2 diabetes show postprandial ED whether acarbose able improve condition .</brief_summary>
	<brief_title>Effects Acarbose Endothelial Function After Mixed Meal Newly Diagnosed Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>age 3575 year type 2 diabetes ( newly diagnose ) well glycemic control ( HbA1c &lt; /= 8.1 ) leucocyte count &gt; 6.2 h CrP &gt; 1 h CrP &gt; 10 type 1 diabetes previous treatment antidiabetic drug</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>